Hims & Hers Health (HIMS) Q2 2026 earnings summary

Executive summary

• Revenue grew 38–40% year-over-year in Q2 2026 to $753–$753.2 million, driven by subscriber growth, international expansion (notably the Eucalyptus acquisition), and AI-powered care initiatives.

• Subscriber base increased by 19% to nearly 2.9–3 million, with 300,000 net new subscribers and monthly revenue per average subscriber up 21% to $92.

• Strategic focus on AI-driven health experience, infrastructure for complex care, and global scale, positioning the platform as a leader in consumer-centric healthcare.

• Net loss was $86–$86.3 million for Q2 2026, primarily due to higher operating expenses, legal contingencies, and restructuring charges.

• Strategic acquisitions in North America, Europe, Australia, and Japan have accelerated global reach.

Financial highlights

• Q2 2026 revenue: $753–$753.2 million, up 38–40% year-over-year; U.S. revenue: $621.8–$622 million, up 16%.

• International revenue increased over 17-fold year-over-year to $131–$131.4 million, with Eucalyptus contributing $40 million.

• Adjusted EBITDA: $60–$60.3 million (8% margin), down from $82.2 million (15% margin) in Q2 2025.

• Gross margin: 64%, down from 76% year-over-year, due to mix shift toward weight loss and international revenue.

• Cash and investments totaled $840–$841 million as of June 30, 2026.

Outlook and guidance

• Q3 2026 revenue guidance: $880–$900 million (47–50% year-over-year growth); adjusted EBITDA: $75–$95 million (9–11% margin).

• Full-year 2026 revenue outlook raised to $3.1–$3.3 billion (32–41% growth); adjusted EBITDA: $275–$325 million (9–10% margin midpoint).

• Long-term ambition: $6.5 billion revenue and $1.3 billion adjusted EBITDA by 2030.

• International business expected to generate at least $600 million in 2026, operating at or near breakeven as scale is prioritized.